Compare Alcon AG (ALC) vs Payoneer Global Inc (PAYO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Payoneer Global Inc — how do they compare? Alcon AG trades at $66.89 (market cap $32.69B), while Payoneer Global Inc trades at $7.1 (market cap $2.40B). The key difference: Alcon AG is far larger — about 13.6× Payoneer Global Inc's market cap, and Alcon AG pays a 0.54% dividend while Payoneer Global Inc pays none. Which is the better fit depends on your goals.
| ALC | PAYO | |
|---|---|---|
Market Cap | $32.69B | $2.40B |
Sector | Health | Technology |
52-Week High | $92.22 | $7.42 |
52-Week Low | $62.02 | $4.27 |
Enterprise Value | $36.28B | $2.14B |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Payoneer Global (PAYO) trades at $7.10, up slightly by 0.14% today, with a bullish technical signal from moving averages and a consensus analyst price target of $8.20. Recent financials show revenue growth to $821.16 million in 2025, though net income declined to $73.19 million, and the company is the subject of a pending $2.75 billion acquisition by Nuvei announced in June 2026.
The acquisition offer at $7.40 per share, below the consensus target, creates uncertainty but provides a near-term floor. Risks include integration challenges and shareholder litigation over deal fairness, while fundamentals like a 79.4% gross margin and positive cash flow support long-term value if the deal falls through.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →
